Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared a post on X about a paper she co-authored with her colleagues, published in Clinical Cancer Research:
“Can we stop excluding brain Mets from clinical trials. These patients need therapy. DART showed that brain Mets did not compromise safety or activity.”
Title: Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609)
Authors: Manmeet S. Ahluwalia, Sophie Solomon, Sandip P. Patel, Zouina Sarfraz, Megan Othus, Young K. Chae, and Razelle Kurzrock
You can read the Full Article in Clinical Cancer Research.
More posts featuring Razelle Kurzrock.
